Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

BACKGROUND: Despite years of research, the treatment options and mortality rate for ovarian cancer remain relatively stagnant. Resistance to chemotherapy and high heterogeneity in mutations contribute to ovarian cancer’s lethality, including many mutations in tumor suppressor p53. Though wild type p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowman, Katherine Redd, Kim, Ji Hoon, Lim, Carol S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492428/
https://www.ncbi.nlm.nih.gov/pubmed/31039796
http://dx.doi.org/10.1186/s13048-019-0514-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492428/
https://www.ncbi.nlm.nih.gov/pubmed/31039796
http://dx.doi.org/10.1186/s13048-019-0514-4

Ejemplares similares